EQS-News: H&R continues its recovery during the year with nine-month figures 2023
EQS-News: H&R GmbH & Co. KGaA
/ Key word(s): 9 Month figures/Quarterly / Interim Statement
H&R continues its recovery during the year with nine-month figures 2023
15.11.2023 / 10:11 CET/CEST
The issuer is solely responsible for the content of this announcement.
H&R GmbH & Co. KGaA: Quarterly Report for third quarter of 2023
- Third quarter delivers highest earnings contribution: EBITDA of EUR 66.6 million in the first nine months
- Further significant improvement in cash positions
- Slightly more optimistic expectations for the year as a whole
Salzbergen, Germany, November 15, 2023. H&R GmbH & Co. KGaA (short: H&R KGaA; ISIN DE000A2E4T77) has confirmed its preliminary sales and earnings figures for the third quarter of 2023: From July to September 2023, the company achieved an operating result (EBITDA - consolidated earnings before income taxes, other financial income and expenses as well as amortization, depreciation and impairment losses and write-ups on intangible assets and property, plant and equipment) of EUR 27.2 million (same period of the previous year: EUR 30.5 million). The recovery during the year continued: The third quarter of 2023 delivered the highest contribution to earnings this year. EBIT closed at EUR 13.0 million, down from last year's EUR 17.2 million. Earnings before taxes (EBT) for Q3-2023 were EUR 9.6 million (Q3-2022: EUR 15.3 million), and the company closed at EUR 7.6 million for consolidated net income attributable to shareholders (Q3-2022: EUR 10.4 million). Sales in the third quarter of the current fiscal year were reduced to EUR 337.2 million (Q3-2022: EUR 418.7 million), mainly due to higher raw material costs compared to the previous year.
Overview of key figures:
in million EUR |
Nine months 2023 |
Nine Months 2022 |
Diff. abs. |
Sales Revenues |
1,036.8 |
1,224.5 |
-187.7 |
ChemPharm REFINING |
634.1 |
802.7 |
-168.6 |
ChemPharm SALES |
380.1 |
401.8 |
-21.7 |
PLASTICS |
38.3 |
34.2 |
4.1 |
Consolidation |
-15.7 |
-14.2 |
-1.5 |
|
|
|
|
Operative Earnings (EBITDA) |
66.6 |
103.3 |
-36.7 |
ChemPharm REFINING |
43.2 |
74.3 |
-31.1 |
ChemPharm SALES |
21.9 |
29.6 |
-7.7 |
PLASTICS |
3.0 |
2.4 |
-0.6 |
Consolidation |
-1.5 |
-3.1 |
1.6 |
|
|
|
|
EBIT |
24.1 |
63.4 |
-39.3 |
Earnings before Taxes |
15.2 |
58.2 |
-43.0 |
Net Income attributable to Shareholders |
11.3 |
40.1 |
-28.8 |
Earnings per Share (in EUR) |
0.30 |
1.08 |
-0.78 |
Operative Cashflow |
101.7 |
-9.0 |
110.7 |
Free Cashflow |
58.4 |
-60.3 |
118.7 |
|
|
|
|
|
Q3 2023 |
Q3 2022 |
Diff. abs. |
Sales Revenues |
337.2 |
418.7 |
-81.5 |
ChemPharm REFINING |
200.9 |
268.4 |
-67.5 |
ChemPharm SALES |
129.0 |
141.9 |
-12.9 |
PLASTICS |
12.0 |
13.1 |
-1.1 |
Consolidation |
-4.7 |
-3.9 |
-0.8 |
|
|
|
|
Operative Earnings (EBITDA) |
27.2 |
30.5 |
-3.3 |
ChemPharm REFINING |
20.9 |
19.4 |
1.5 |
ChemPharm SALES |
8.0 |
10.9 |
-2.9 |
PLASTICS |
0.0 |
1.1 |
-1.1 |
Consolidation |
-1.7 |
-0.9 |
-0.8 |
|
|
|
|
EBIT |
13.0 |
17.2 |
-4.2 |
Earnings before Taxes |
9.6 |
15.3 |
-5.7 |
Net Income attributable to Shareholders |
7.6 |
10.4 |
-2.8 |
Earnings per Share (in EUR) |
0.20 |
0.28 |
-0.08 |
Operative Cashflow |
44.6 |
-7.6 |
52.5 |
Free Cashflow |
33.8 |
-31.6 |
65.4 |
|
|
|
|
|
30/09/2023 |
31/12/2022 |
Diff. abs. |
Balance Sheet Total |
926.9 |
962.1 |
-35.2 |
Equity |
466.9 |
471.2 |
-4.3 |
Equity Ratio (in %, difference in percentage points) |
50.4 |
49.0 |
1.4 |
Following the increase in the lower range of its guidance two weeks ago, the company currently continues to expect to achieve the target of EUR 80.0 million minimum. The upper range of EUR 90.0 million remains unchanged.
For further information on the business and earnings development, the company refers to the Quarterly Statement on Q3 2023 published today, which can be downloaded from www.hur.com in the "Investor Relations" section.
Contact information:
H&R GmbH & Co. KGaA, Head of Investor Relations/Communications, Ties Kaiser
Neuenkirchener Strasse 8, 48499 Salzbergen
Tel.: +49 40 43218-321, Fax: +49 40 43218-390
e-mail: [email protected] ; www.hur.com
H&R GmbH & Co. KGaA:
H&R KGaA is a specialty-chemicals company listed on the Frankfurt Stock Exchange's Prime Standard segment. It develops and manufactures fossil-, biomass-, synthetic- and recycle-based hydrocarbon chemical and pharmaceutical specialty products and produces high-precision plastic parts.
Forward-looking statements and forecasts:
This press release contains forward-looking statements. The statements are based on the current estimates and forecasts by the Executive Board and the information available to the Board at this time. These forward-looking statements do not provide any warranty for the future developments and results contained therein. The future developments and results are dependent on a number of factors; they entail various risks and contingencies and are based on assumptions which could prove to be incorrect. We do not assume any responsibility for updating the forward-looking statements contained in this press release.
15.11.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.eqs-news.com
|
Language: |
English |
Company: |
H&R GmbH & Co. KGaA |
|
Neuenkirchener Str. 8 |
|
48499 Salzbergen |
|
Germany |
Phone: |
+49 (0)40 43 218 321 |
Fax: |
+49 (0)40 43 218 390 |
E-mail: |
[email protected] |
Internet: |
www.hur.com |
ISIN: |
DE000A2E4T77 |
WKN: |
A2E4T7 |
Listed: |
Regulated Market in Dusseldorf, Frankfurt (Prime Standard), Hamburg; Regulated Unofficial Market in Berlin, Hanover, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: |
1774069 |
|
End of News |
EQS News Service |
1774069 15.11.2023 CET/CEST
Die wichtigsten Finanzdaten auf einen Blick
|
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
Umsatzerlöse1 |
1.025,11 |
1.114,15 |
1.075,32 |
873,03 |
1.188,43 |
1.576,04 |
1.352.260,00 |
EBITDA1,2 |
97,39 |
74,70 |
52,90 |
55,72 |
132,66 |
124,90 |
92,66 |
EBITDA-Marge3 |
9,50 |
6,70 |
4,92 |
6,38 |
11,16 |
7,92 |
|
EBIT1,4 |
54,29 |
40,17 |
7,40 |
-0,35 |
81,72 |
70,23 |
30,68 |
EBIT-Marge5 |
5,30 |
3,61 |
0,69 |
-0,04 |
6,88 |
4,46 |
0,00 |
Jahresüberschuss1 |
29,50 |
22,32 |
0,08 |
-7,83 |
52,53 |
45,36 |
10,56 |
Netto-Marge6 |
2,88 |
2,00 |
0,01 |
-0,90 |
4,42 |
2,88 |
0,00 |
Cashflow1,7 |
46,19 |
23,32 |
95,86 |
60,15 |
37,42 |
37,98 |
119,07 |
Ergebnis je Aktie8 |
0,88 |
0,59 |
-0,04 |
-0,24 |
1,35 |
1,15 |
0,28 |
Dividende8 |
0,40 |
0,00 |
0,00 |
0,00 |
0,00 |
0,10 |
0,00 |
Quelle: boersengefluester.de und Firmenangaben
Geschäftsbericht 2023 - Kostenfrei herunterladen.
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de
Wirtschaftsprüfer: Grant Thornton
|
INVESTOR-INFORMATIONEN |
©boersengefluester.de |
H&R |
WKN |
Kurs in € |
Einschätzung |
Börsenwert in Mio. € |
A2E4T7 |
3,270 |
Kaufen |
121,72 |
KGV 2025e |
KGV 10Y-Ø |
BGFL-Ratio |
Shiller-KGV |
10,22 |
11,05 |
0,54 |
5,14 |
KBV |
KCV |
KUV |
EV/EBITDA |
0,30 |
1,02 |
0,09 |
2,87 |
Dividende '22 in € |
Dividende '23 in € |
Div.-Rendite '23 in % |
Hauptversammlung |
0,10 |
0,10 |
3,06 |
27.05.2025 |
Q1-Zahlen |
Q2-Zahlen |
Q3-Zahlen |
Bilanz-PK |
15.05.2024 |
14.08.2024 |
14.11.2024 |
28.03.2024 |
Abstand 60Tage-Linie |
Abstand 200Tage-Linie |
Performance YtD |
Performance 52 Wochen |
-11,76% |
-25,80% |
-30,13% |
-32,85% |
|
|